ORIG3N, an innovative biotech company that creating the world’s largest blood cell repository for induced pluripotent stem cell (iPS cell) production. I first met James Lovgren, Chief Business Officer of ORIG3N, at the World Stem Cell Summit in 2015. As a result of that connection and conversation, I am pleased to share this interview with him below. [Read more…]
BioInformant's Founder, Cade Hildreth, has interviewed hundreds of key opinion leaders (KOL's) from across the stem cell industry.
Inside Scoop on Biostage, a World Leader in Bioengineered Organs
Biostage is a clinical-stage company specializing in bioengineered organ implants to treat cancer and other conditions involving the esophagus, bronchus and trachea. In August 2017, Biostage transplanted its esophageal implant product into its first patient worldwide, a 75-year old man with cancer. On the heels of this historic accomplishment, I am pleased to share this interview with Jim McGorry, President and CEO at Biostage, Inc. In this interview, we discuss the company’s vision, its research partnerships, clinical trial strategy, and five-year goals.
Please note that this interview was conducted prior to Biostage’s breach and failure to fund by First Pecos.
Read on to learn more about how Biostage is introducing bioengineered organ implants to the regenerative medicine landscape. [Read more…]
Will Glycostem Release 1st Allogeneic NK Cell Product with Off-the-Shelf Potential?
This interview comes shortly after Novartis became the first company to get a gene therapy approved in the United States, the CAR-T cell therapy, Kymriah®. The historic event demonstrates to investors, the public and funding providers alike that cell therapy is a sector that has emerged, no longer one that is evolving in the future. There are close to 40 companies developing redirected T cells or NK cells for therapeutic use. There are also 800+ cell therapy clinical trials underway around the world, and a considerable amount of research and preclinical work taking place across the cell therapy sector.
In the light of the recent Gilead takeover of Kite Pharma for $11 billion, the cellular immunotherapy sector is in focus among both investors and oncology and non-oncology companies. The search for the “next Kite” has begun!
Glycostem is a 10-year old clinical stage cellular immunotherapy company based in The Netherlands. The uniqueness around Glycostem, beyond that it is a privately funded company with strong phase I safety clinical trial data, is that it may become the first company with an allogeneic off-the- shelf product (oNKord®). This would potentially position NK cell technology to leapfrog CAR-T cell products, due to a safer profile, lower production costs, off-the- shelf status and positive clinical trial data. [Read more…]
Genetically Modified Muscle Progenitor Cells with Stem Cell Medicine Ltd.
In the world of stem cells, there are a number of well-recognized market participants that receive a great deal of attention from the stem cell community.
At the same time, there are brilliant companies that quietly operate under the radar screen, building themselves up one intelligent and methodical step at a time. [Read more…]
Cord Blood Transplantation with Dr. Milano of Fred Hutchinson
I had the honor of interviewing Dr. Filippo Milano, Associate Director of Cord Blood Transplantation at the Fred Hutchinson Cancer Research Centre about cord blood transplantation. In this interview, Dr. Milano speaks about trends in cord blood transplantation (CBT) that are affecting the global cord blood industry. [Read more…]
- « Previous Page
- Next Page »